Must-See: Jim Cramer’s 10 Best Stock Picks for Investors Right Now

8. Moderna Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 39

Jim Cramer reported that Moderna Inc. (NASDAQ:MRNA)’s shares fell by 10% after the company announced it would cut costs by $1.1 billion. Along with this, Moderna Inc. (NASDAQ:MRNA) revealed plans to launch 10 new products by 2027. Moderna Inc. (NASDAQ:MRNA) is navigating challenges as its Covid vaccine business declines. Moderna Inc. (NASDAQ:MRNA)’s second commercially available product, RSV vaccines for seniors, was approved four months ago.

“Moderna shares dropped 10% after the biotech announced $1.1 billion in cut costs. It also announced plans for 10 new products by 2027. Moderna is trying to figure out the future as its Covid vaccine business rapidly declines. The company’s second commercially available product, RSV shots for seniors, was approved four months ago.”

Moderna, Inc. (NASDAQ:MRNA) presents a strong investment case due to its promising vaccine pipeline, progress in cancer treatment, and solid financial position. Moderna, Inc. (NASDAQ:MRNA)’s technology is expanding beyond COVID-19 vaccines. Notable developments include a next-generation COVID-19 vaccine (mRNA-1283), a successful Phase 3 trial for a combined flu and COVID-19 vaccine, and FDA approval for its RSV vaccine.

Moderna, Inc. (NASDAQ:MRNA)’s collaboration with Merck & Co., Inc. (NYSE:MRK) on mRNA-based cancer treatments, like the melanoma therapy mRNA-4157, also shows potential for new revenue streams. Even though Moderna Inc. (NASDAQ:MRNA)  has faced a decline in COVID-19 vaccine sales this year, it remains financially healthy, with expected cash and investments around $9 billion by year-end. This strong financial base supports continued research and growth.

Analysts are optimistic, forecasting Moderna Inc. (NASDAQ:MRNA) could reach between $70 and $105. Overall, despite current short-term challenges, Moderna, Inc. (NASDAQ:MRNA)’s long-term potential in vaccines and therapeutics makes it a compelling investment.